Momenta Gets Rivals' Sale Of Generic Lovenox Barred

Law360, San Diego (October 28, 2011, 9:51 PM EDT) -- Massachusetts drugmaker Momenta Pharmaceuticals Inc. on Friday won a preliminary injunction that blocks rivals Watson Pharmaceuticals Inc., Amphastar Pharmaceuticals Inc. and International Medical Systems Ltd. from selling a competing generic version of the blood-thinning drug Lovenox in the U.S.

A Massachusetts federal court granted Momenta’s injunction bid, finding that the plaintiff showed a likelihood of success on the merits of its claim that its U.S. Patent Number 7,575,886 was valid and infringed by the defendants’ enoxaparin sodium generic drug.

The injunction bars Watson, Amphastar and its...
To view the full article, register now.